Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Valrubicin |
Synonyms | |
Therapy Description |
Valstar (valrubicin) is an anthracycline that is metabolized into compounds that inhibit topoisomerase II, resulting in inhibition of DNA synthesis and potentially leading to decreased tumor growth (PMID: 19145271, PMID: 20554745). Valstar (valrubicin) is FDA-approved for treatment of BCG-refractory urinary bladder carcinoma in situ (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Valrubicin | Valstar | Antibiotic Ad 32|AD-32 | Chemotherapy - Anthracycline 13 TOPO2 inhibitor 5 | Valstar (valrubicin) is an anthracycline that is metabolized into compounds that inhibit topoisomerase II, resulting in inhibition of DNA synthesis and potentially leading to decreased tumor growth (PMID: 19145271, PMID: 20554745). Valstar (valrubicin) is FDA-approved for treatment of BCG-refractory urinary bladder carcinoma in situ (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01438112 | Phase II | Valrubicin Mitomycin C CG0070 Interferon gamma Gemcitabine | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND) | Terminated | USA | 0 |